ST101
Phase 2Small molecule
ST101 is one of 36 small molecule programs targeting Essential Tremor. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
46 competitors in Essential Tremor
#DrugCompanyPhaseTrials
1Namenda
AbbVieApproved
Marinol
Alnylam PharmaceuticalsApproved
Epidiolex
Jazz PharmaceuticalsApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Topamax
WWim Janssens
Approved
Mirapex
Boehringer IngelheimPhase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Xyrem
Jazz PharmaceuticalsPhase 2
Zonegran
AAzurity Pharmaceuticals
Phase 2
Fycompa
CCatalyst Biosciences
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Alzheimer's Disease2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ST101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSonexa Therapeutics, Inc.